|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:Kuur_Therapeutics
|
|
gptkbp:business_model
|
Biopharmaceuticals
|
|
gptkbp:can_lead_to
|
KUR-502
|
|
gptkbp:ceo
|
gptkb:Dr._Johnson_Lau
|
|
gptkbp:clinical_trial
|
Ongoing
Phase 3 trials
Multiple sites
Phase 1, Phase 2, Phase 3
Published in journals
|
|
gptkbp:collaborations
|
gptkb:University_of_Buffalo
With academic institutions
|
|
gptkbp:committee
|
Established
|
|
gptkbp:community_engagement
|
gptkb:battle
|
|
gptkbp:community_involvement
|
Engaged
|
|
gptkbp:employees
|
200+
|
|
gptkbp:financial_performance
|
Quarterly
Published
|
|
gptkbp:focus
|
gptkb:healthcare_organization
|
|
gptkbp:founded
|
gptkb:2003
|
|
gptkbp:founder
|
gptkb:R._Scott_Greer
|
|
gptkbp:global_presence
|
gptkb:battle
|
|
gptkbp:governed_by
|
Active
|
|
gptkbp:headcount
|
Increasing
|
|
gptkbp:headquarters
|
gptkb:Buffalo,_New_York
|
|
gptkbp:healthcare
|
gptkb:battle
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Athenex, Inc.
|
|
gptkbp:industry
|
Pharmaceuticals
|
|
gptkbp:invention
|
Multiple patents granted
|
|
gptkbp:investment
|
gptkb:Company
Active
Institutional investors
Regularly provided
|
|
gptkbp:language_of_instruction
|
Multiple drug candidates
|
|
gptkbp:location
|
gptkb:United_States
|
|
gptkbp:market
|
Scheduled
|
|
gptkbp:market_cap
|
$300 million (2021)
|
|
gptkbp:marketing_strategy
|
Focused on oncology
|
|
gptkbp:partnership
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:partnerships
|
Explored
Various pharmaceutical companies
|
|
gptkbp:products
|
Cancer therapies
|
|
gptkbp:publishes
|
Contributed to
|
|
gptkbp:receives_funding_from
|
Secured
|
|
gptkbp:regulatory_compliance
|
Compliant
|
|
gptkbp:research_and_development
|
gptkb:battle
|
|
gptkbp:research_areas
|
Hematology
|
|
gptkbp:research_focus
|
Cancer treatment
Cell therapy
|
|
gptkbp:revenue
|
$50 million (2020)
|
|
gptkbp:stock_exchange
|
Regularly held
|
|
gptkbp:strategic_importance
|
Expand oncology portfolio
|
|
gptkbp:subsidiary
|
gptkb:Kuur_Therapeutics
|
|
gptkbp:sustainability_initiatives
|
Implemented
|
|
gptkbp:symbol
|
ATNX
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:type
|
gptkb:football_club
|
|
gptkbp:website
|
www.athenex.com
|
|
gptkbp:bfsParent
|
gptkb:Bayer_Group
|
|
gptkbp:bfsLayer
|
3
|